Arini Captial Management Ltd Acquires New Position in Claritev $CTEV

Arini Captial Management Ltd acquired a new stake in Claritev (NYSE:CTEV) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 1,503,892 shares of the company’s stock, valued at approximately $64,291,000. Claritev comprises approximately 42.8% of Arini Captial Management Ltd’s holdings, making the stock its biggest position. Arini Captial Management Ltd owned approximately 0.09% of Claritev at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CTEV. Rhumbline Advisers bought a new stake in Claritev in the third quarter valued at about $567,000. JPMorgan Chase & Co. bought a new stake in Claritev in the third quarter valued at about $1,245,000. Vanguard Group Inc. bought a new stake in Claritev in the third quarter valued at about $27,483,000. Citigroup Inc. bought a new stake in Claritev in the third quarter valued at about $2,025,000. Finally, Ameritas Investment Partners Inc. bought a new stake in Claritev in the third quarter valued at about $42,000. 87.15% of the stock is owned by institutional investors.

Claritev Stock Performance

CTEV stock opened at $29.71 on Thursday. The stock has a market capitalization of $506.56 million, a price-to-earnings ratio of -1.71 and a beta of 0.77. Claritev has a 1 year low of $11.50 and a 1 year high of $74.07. The stock’s fifty day moving average is $23.71 and its two-hundred day moving average is $26.01.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on CTEV. Guggenheim reissued a “buy” rating on shares of Claritev in a report on Tuesday, February 24th. Wells Fargo & Company decreased their price target on shares of Claritev from $30.00 to $22.00 and set an “equal weight” rating for the company in a report on Thursday, March 19th. Citigroup reaffirmed a “buy” rating on shares of Claritev in a report on Wednesday, May 13th. Barclays initiated coverage on shares of Claritev in a report on Friday, April 24th. They issued an “overweight” rating and a $28.00 price target for the company. Finally, Wall Street Zen lowered shares of Claritev from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.67.

Claritev Company Profile

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.